David Hollenback

577 total citations
21 papers, 419 citations indexed

About

David Hollenback is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, David Hollenback has authored 21 papers receiving a total of 419 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 4 papers in Oncology and 4 papers in Epidemiology. Recurrent topics in David Hollenback's work include Protein Kinase Regulation and GTPase Signaling (5 papers), Liver Disease Diagnosis and Treatment (4 papers) and Lipid metabolism and biosynthesis (4 papers). David Hollenback is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (5 papers), Liver Disease Diagnosis and Treatment (4 papers) and Lipid metabolism and biosynthesis (4 papers). David Hollenback collaborates with scholars based in United States, Austria and Norway. David Hollenback's co-authors include Jack W. Singer, Lynn Bonham, Thayer White, Michael Coon, David G. Breckenridge, David W. M. Leung, John Tulinsky, Kathy Liu, Bruno Marchand and Bryan C. Fuchs and has published in prestigious journals such as Biochemistry, Clinical Cancer Research and Journal of Hepatology.

In The Last Decade

David Hollenback

19 papers receiving 406 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Hollenback United States	9	212	134	131	75	70	21	419
Pia Sulas Italy	12	242 1.1×	120 0.9×	34 0.3×	54 0.7×	37 0.5×	15	464
Robert Sherwin United States	4	267 1.3×	117 0.9×	28 0.2×	47 0.6×	30 0.4×	7	478
M M Simile Italy	14	411 1.9×	64 0.5×	54 0.4×	41 0.5×	45 0.6×	21	616
Myeong‐Jin Nam South Korea	7	233 1.1×	130 1.0×	15 0.1×	65 0.9×	60 0.9×	8	392
Laura Gómez‐Santos Spain	8	243 1.1×	69 0.5×	25 0.2×	55 0.7×	34 0.5×	21	380
Annalisa Morgano Italy	11	253 1.2×	125 0.9×	23 0.2×	45 0.6×	28 0.4×	15	481
Shuoyi Jiang China	9	289 1.4×	124 0.9×	33 0.3×	44 0.6×	30 0.4×	12	439
Yolanda Chico Spain	12	152 0.7×	71 0.5×	36 0.3×	15 0.2×	14 0.2×	24	332
Claudine Grégori France	14	237 1.1×	27 0.2×	39 0.3×	29 0.4×	39 0.6×	18	386
Michio Oda Japan	11	116 0.5×	58 0.4×	35 0.3×	126 1.7×	9 0.1×	18	411

Countries citing papers authored by David Hollenback

Since Specialization

Citations

This map shows the geographic impact of David Hollenback's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Hollenback with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Hollenback more than expected).

Fields of papers citing papers by David Hollenback

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Hollenback. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Hollenback. The network helps show where David Hollenback may publish in the future.

Co-authorship network of co-authors of David Hollenback

This figure shows the co-authorship network connecting the top 25 collaborators of David Hollenback. A scholar is included among the top collaborators of David Hollenback based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Hollenback. David Hollenback is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hollenback, David, Eva Hambruch, Andreas Schulz, et al.. (2024). Development of Cilofexor, an Intestinally-Biased Farnesoid X Receptor Agonist, for the Treatment of Fatty Liver Disease. Journal of Pharmacology and Experimental Therapeutics. 389(1). 61–75. 3 indexed citations

Fuchs, Claudia, Hubert Scharnagl, Ruchi Gupta, et al.. (2023). Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2-/- mouse model of sclerosing cholangitis. JHEP Reports. 5(11). 100874–100874. 15 indexed citations

Vijayakumar, Archana, Ting Wang, Saritha Kusam, et al.. (2022). Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis. Hepatology Communications. 6(9). 2298–2309. 9 indexed citations

Bates, Jamie, Archana Vijayakumar, Sarani Ghoshal, et al.. (2020). Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation. Journal of Hepatology. 73(4). 896–905. 154 indexed citations

Vijayakumar, Archana, Ting Wang, David Hollenback, et al.. (2020). Efficacy and safety of an acetyl CoA carboxylase inhibitor are improved in combination with PPAR agonists in a dyslipidemic rat model. Journal of Hepatology. 73. S656–S656.

Hambruch, Eva, David Hollenback, Olaf Kinzel, et al.. (2019). FRI-303-How to develop a differentiated FXR agonist: GS-9674 shows a reduced side effect profile in mice, monkeys amd human phase 1 studies compared to its predecessor Px-102. Journal of Hepatology. 70(1). e528–e529. 2 indexed citations

Bates, Jamie, David Hollenback, Anna Zagórska, et al.. (2018). Combination of an FXR agonist and an ACC inhibitor increases anti-fibrotic efficacy in rodent models of NASH. Journal of Hepatology. 68. S395–S396.

Wei, Ling, David Hollenback, Saritha Kusam, et al.. (2018). ACC inhibitor demonstrates potent anti-fibrotic activity in vitro and in vivo. Journal of Hepatology. 68. S399–S400. 2 indexed citations

Zagórska, Anna, David Hollenback, Grant R. Budas, et al.. (2017). Combination of an ASK1 inhibitor and FXR agonist increases efficacy in a mouse model of non-alcoholic steatohepatitis. Journal of Hepatology. 66(1). S19–S20. 3 indexed citations

10.

Taleban, Sasha, Helén L. Dichek, Samir S. Deeb, et al.. (2008). Energy balance in congenital generalized lipodystrophy type I. Metabolism. 57(8). 1155–1161. 8 indexed citations

11.

Rosée, Paul La, Taiping Jia, Nicolai Härtel, et al.. (2006). Antileukemic Activity of Lysophosphatidic Acid Acyltransferase-β Inhibitor CT32228 in Chronic Myelogenous Leukemia Sensitive and Resistant to Imatinib. Clinical Cancer Research. 12(21). 6540–6546. 23 indexed citations

12.

Chipman, Stewart D., R. Rosler, Lynn Bonham, et al.. (2006). 643 POSTER Energy dependent uptake of paclitaxel poliglumex by human NSCLC tumor and murine macrophage-like cell lines. European Journal of Cancer Supplements. 4(12). 194–194. 1 indexed citations

13.

Hollenback, David, Lynn Bonham, Christopher Tompkins, et al.. (2005). Substrate specificity of lysophosphatidic acid acyltransferase β—evidence from membrane and whole cell assays. Journal of Lipid Research. 47(3). 593–604. 50 indexed citations

14.

Hong, Feng, David Hollenback, Jack W. Singer, & Peter Klein. (2005). Diamino-C,N-diarylpyridine positional isomers as inhibitors of lysophosphatidic acid acyltransferase-β. Bioorganic & Medicinal Chemistry Letters. 15(21). 4703–4707. 8 indexed citations

15.

Taleban, Sasha, et al.. (2005). 450 LOW LEVELS OF LYSOPHOSPHATIDIC ACID ACETYLTRANSFERASEβ ACTIVITY IN CONGENITAL GENERALIZED LIPODYSTROPHY. Journal of Investigative Medicine. 53(1). S157.2–S157. 1 indexed citations

16.

Pagel, John M., Lynn Bonham, Robert C. Hackman, et al.. (2005). Induction of Apoptosis Using Inhibitors of Lysophosphatidic Acid Acyltransferase-β and Anti-CD20 Monoclonal Antibodies for Treatment of Human Non-Hodgkin's Lymphomas. Clinical Cancer Research. 11(13). 4857–4866. 30 indexed citations

17.

Bonham, Lynn, David W. M. Leung, Thayer White, et al.. (2003). Lysophosphatidic acid acyltransferase-β: a novel target for induction of tumour cell apoptosis. Expert Opinion on Therapeutic Targets. 7(5). 643–661. 39 indexed citations

18.

Bonham, Lynn, David W. M. Leung, Thayer White, et al.. (2003). Lysophosphatidic acid acyltransferase-?: a novel target for induction of tumour cell apoptosis. Expert Opinion on Therapeutic Targets. 7(5). 643–661. 1 indexed citations

19.

Coon, Michael, Alexey Ball, David Hollenback, et al.. (2003). Inhibition of lysophosphatidic acid acyltransferase beta disrupts proliferative and survival signals in normal cells and induces apoptosis of tumor cells.. PubMed. 2(10). 1067–78. 49 indexed citations

20.

Hollenback, David & John A. Glomset. (1998). On the Relation between a Stearoyl-Specific Transacylase from Bovine Testis Membranes and a Copurifying Acyltransferase. Biochemistry. 37(1). 363–376. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact